Congressional Testimony

2001

October

• Bernard Schwetz, D.V.M, Ph.D., October 10, 2001
  Acting Principal Deputy Commissioner, Food and Drug Administration, Committee on Governmental Affairs to discuss the Federal food safety system and ensuring the safety of the food supply is a top priority for HHS and the Administration.

September

• John Taylor, September 10, 2001
  Director, Office of Enforcement, Office of Regulatory Affairs before the Special Committee on Aging to discuss health fraud specifically as it relates to dietary supplements.
• William K. Hubbard, September 5, 2001
  Senior Associate Commissioner for Policy, Planning and Legislation before the Subcommittee on Consumer Affairs, Foreign Commerce, and Tourism to discuss our mutual concerns related to the importation of drugs into the United States.

July

• Nancy M. Ostrove, Ph.D., July 24, 2001
  Deputy Director, Division of Drug Marketing, Advertising and Communications, Center for Drug Evaluation and Research before the House Subcommittee on Consumer Affairs, Foreign Commerce, and Tourism to discuss direct-to-consumer promotion of prescription drugs.

June

• Robert J. Temple, M.D., June 20, 2001
  Associate Director for Medical Policy, Center for Drug Evaluation and Research to discuss an important issue of the availability of investigational drugs for what is commonly referred to as compassionate use.
• Janet Woodcock, M.D., June 13, 2001
  Director, Center for Drug Evaluation and Research-- Subcommittee on Health to update you on three important areas that CDER is continuing to work on.
• William K. Hubbard, June 7, 2001
  Senior Associate Commissioner for Policy, Planning and Legislation -- Submittee on Oversight and Investigations to discuss our mutual concerns related to the importation of drugs into the United States (U.S.).

May

• Kathryn C. Zoon, Ph.D., May 24, 2001 Director Center for Biologics Evaluation and Research (CBER) -- Permanent Subcommittee on Investigations to discuss the regulation of many of the different types of human tissue and cells used in transplantation.
• Gary Buehler, RPh, May 24, 2001
  Acting Director of the Office of Generic Drugs, Center for Drug Evaluation and Research (CDER), --Committee on the Judiciary to discuss FDA's implementation of provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) which govern the generic drug approval process
• Bernard Schwetz, D.V.M, Ph.D., May 10, 2001
  Acting Principal Deputy Commissioner, Food and Drug Administration, United States Senate, Committee on Appropriations to discuss some of the accomplishments, as well as the challenges FDA faces in the new century.
• Janet Woodcock, M.D., May 8, 2001
  Director, Center for Drug Evaluation and Research-- Committee on Health, Education, Labor and Pensions to discuss FDA's role with respect to implementation of the pediatric exclusivity provisions.
• Linda Suydam, D.P.A., May 3, 2001
  Senior Associate Commissioner at the Food and Drug Administration-- Committee on Energy and Commerce to discuss the Agency's progress and success in implementing the Food and Drug Administration Modernization Act of 1997 (FDAMA or Modernization Act).

April

• Karen Midthun, M.D., April 24, 2001
  Director, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research-- Before the Committee on Government Reform to explain FDA's ongoing efforts in response to the issue of vaccines and autism.
• Stephen Sundlof, D.V.M., Ph.D, April 4, 2001
  Director, Center for Veterinary Medicine -- Before the Committee on Commerce, Science, and Transportation to discuss the measures by the Federal government to prevent bovine sponiform encephalopathy (BSE) or "Mad Cow Disease" from occurring in the United States.

March

• Kathryn C. Zoon, Ph.D., March 28, 2001
  Director, Center for Biologics Evaluation and Research -- Before the Subcommittee on Oversight and Investigations to discuss FDA's views on the use of cloning technology to clone a human being as a cause for public health concern.
• Joseph A Levitt, Esq., March 20, 2001
  Director of the Center for Food Safety and Applied Nutrition/FDA -- Before the Committee on Government Reform to update you on FDA's progress in the area of dietary supplements since I testified before this committee on May 27, 1999.
• Bernard Schwetz, D.V.M, Ph.D., March 8, 2001
  Acting Principal Deputy Commissioner
  Food and Drug Administration, United States House of Representatives, Committee on Appropriations to discuss some of the accomplishments, as well as the challenges FDA faces in the new century.